AVO.L Regulatory News (AVO)

25 October 2013

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Board Changes

Advanced Oncotherapy (AIM: AVO) is pleased to announce the appointment of Sanjeev Pandya as acting Chief Operating Officer, with immediate effect, to replace Dr Sneh Khemka who has left the Board and the Company to pursue his career elsewhere.

Sanjeev Pandya trained and practised as an orthopaedic surgeon in the NHS in the UK and in developing countries before working as a strategy consultant with McKinsey & Company. He then spent two years at Pfizer Global Pharmaceuticals division before joining Lehman Brothers as an investment banker in healthcare M&A. More recently, he has worked as an independent consultant in Russia and at Bupa in London. He has a medical degree from Trinity College, Cambridge and an MBA from INSEAD.

The Company is also pleased to announce the appointment of Professor Christopher Nutting as a Non-Executive Director with immediate effect. Professor Nutting will also join the Company's Medical Advisory Board, chaired by Dr Nick Plowman, Senior Clinical Oncologist to St Bartholomew's Hospital and The Hospital for Sick Children Great Ormond Street, London.

Professor Nutting replaces Professor Chris Boshoff who has resigned as a Non-Executive Director in order to take up an appointment as Vice President for Translational Oncology at Pfizer, Inc., a position based in La Jolla, San Diego, California.

Professor Nutting is Consultant Clinical Oncologist and Chair in Radiation Oncology at the Royal Marsden Hospital, and The Institute of Cancer Research London. He is the Past President of the British Oncological Association. He is a world leading oncologist specialising in the management of cancer of the head and neck, thyroid, thorax and other forms. Professor Nutting is an expert in solid cancer treatment with state of the art radiotherapy techniques designed to reduce complications of treatment and improve cure rates.

There are no disclosures to be made regarding Professor Nutting's appointment under paragraph (g) of Schedule 2 of the AIM Rules.

Advanced Oncotherapy's Chairman, Lord Evans of Watford, said, "I am delighted to welcome Professor Chris Nutting to the Board. His background and current daily experience of radiotherapy treatment qualify him as an ideal team member to help us develop and launch our game changing cancer treatment technology. I am also delighted that Sanjeev has agreed to join us and am sure that his energy and commercial experience will add great value to the executive team. Finally, I thank Chris Boshoff and Sneh Khemka for their contribution to date and wish them well in their new roles."

Commenting on his appointment, Professor Nutting said, "I believe that practitioners around the world will be as excited as I am about Advanced Oncotherapy's technology which is set to deliver better outcomes to more cancer patients."

For further information, please visit www.advancedoncotherapy.comor contact:

About Advanced Oncotherapy Plc

1. AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2. AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of proprietary radiotherapy equipment called LIGHT. This patented technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3. AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK through BMI, Spire and other hospitals.

-ends-